(Q34233555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

Lambert-Eaton myasthenic syndrome

16 January 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jan J Verschuuren

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Bethan Lang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1098-1107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Evidence of underdiagnosis of myasthenia gravis in older people

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The Eaton-Lambert syndrome and autoimmune disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Eaton-Lambert syndrome and malignant thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Thymoma with Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome and follicular thymic hyperplasia in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Chronic Myeloid Leukaemia and a Myasthenic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

LAMBERT-EATON MYASTHENIC SYNDROME WITH PURE OCULAR WEAKNESS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The Eaton-Lambert syndrome in ocular myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome with pure ocular weakness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Transient neonatal Lambert-Eaton syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Transient neonatal Lambert-Eaton syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Calcium channels link the muscle-derived synapse organizer laminin β2 to Bassoon and CAST/Erc2 to organize presynaptic active zones

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

A synaptic laminin–calcium channel interaction organizes active zones in motor nerve terminals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Myasthenic syndrome (Eaton-Lambert syndrome) associated with pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Guidelines for treatment of autoimmune neuromuscular transmission disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Potency of 3,4-Diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970245-9

7 January 2021

10.1016/S1474-4422(11)70245-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094130%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference